JP2018525417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525417A5 JP2018525417A5 JP2018510483A JP2018510483A JP2018525417A5 JP 2018525417 A5 JP2018525417 A5 JP 2018525417A5 JP 2018510483 A JP2018510483 A JP 2018510483A JP 2018510483 A JP2018510483 A JP 2018510483A JP 2018525417 A5 JP2018525417 A5 JP 2018525417A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- composition
- day
- patient
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 40
- 210000001744 T-lymphocyte Anatomy 0.000 claims 32
- 208000017604 Hodgkin disease Diseases 0.000 claims 9
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 9
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 9
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 9
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 9
- 230000000306 recurrent effect Effects 0.000 claims 9
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 8
- 229960004397 cyclophosphamide Drugs 0.000 claims 8
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 208000024908 graft versus host disease Diseases 0.000 claims 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 7
- 238000001727 in vivo Methods 0.000 claims 7
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 6
- 206010003571 Astrocytoma Diseases 0.000 claims 6
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 6
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 5
- 238000011269 treatment regimen Methods 0.000 claims 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 3
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 claims 3
- 206010006143 Brain stem glioma Diseases 0.000 claims 3
- 208000004139 Choroid Plexus Neoplasms Diseases 0.000 claims 3
- 208000004378 Choroid plexus papilloma Diseases 0.000 claims 3
- 208000037156 Choroid plexus tumor Diseases 0.000 claims 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 3
- 208000021309 Germ cell tumor Diseases 0.000 claims 3
- 208000032612 Glial tumor Diseases 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 3
- 208000000172 Medulloblastoma Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 201000004404 Neurofibroma Diseases 0.000 claims 3
- 201000010133 Oligodendroglioma Diseases 0.000 claims 3
- 208000037064 Papilloma of choroid plexus Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 claims 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 3
- 230000000735 allogeneic effect Effects 0.000 claims 3
- 208000006571 choroid plexus carcinoma Diseases 0.000 claims 3
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 210000005259 peripheral blood Anatomy 0.000 claims 3
- 239000011886 peripheral blood Substances 0.000 claims 3
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- 229960001967 tacrolimus Drugs 0.000 claims 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 3
- 230000000007 visual effect Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 230000003352 fibrogenic effect Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022110221A JP2022133453A (ja) | 2015-08-25 | 2022-07-08 | 幹細胞移植方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562209721P | 2015-08-25 | 2015-08-25 | |
| US62/209,721 | 2015-08-25 | ||
| PCT/US2016/048738 WO2017035375A1 (en) | 2015-08-25 | 2016-08-25 | Methods for stem cell transplantation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110221A Division JP2022133453A (ja) | 2015-08-25 | 2022-07-08 | 幹細胞移植方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018525417A JP2018525417A (ja) | 2018-09-06 |
| JP2018525417A5 true JP2018525417A5 (enExample) | 2019-10-03 |
| JP7105188B2 JP7105188B2 (ja) | 2022-07-22 |
Family
ID=58101080
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510483A Active JP7105188B2 (ja) | 2015-08-25 | 2016-08-25 | 幹細胞移植方法 |
| JP2022110221A Pending JP2022133453A (ja) | 2015-08-25 | 2022-07-08 | 幹細胞移植方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110221A Pending JP2022133453A (ja) | 2015-08-25 | 2022-07-08 | 幹細胞移植方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190183930A1 (enExample) |
| EP (2) | EP4458953A3 (enExample) |
| JP (2) | JP7105188B2 (enExample) |
| KR (2) | KR20180041229A (enExample) |
| CN (2) | CN108025023A (enExample) |
| AU (2) | AU2016312610B2 (enExample) |
| CA (1) | CA2996522A1 (enExample) |
| ES (1) | ES2984387T3 (enExample) |
| IL (1) | IL257678B2 (enExample) |
| WO (1) | WO2017035375A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180041229A (ko) * | 2015-08-25 | 2018-04-23 | 유에이비 리서치 파운데이션 | 줄기 세포 이식을 위한 방법 |
| CN117298268A (zh) * | 2016-03-14 | 2023-12-29 | 千禧制药公司 | 治疗或预防移植物抗宿主疾病的方法 |
| WO2018107134A1 (en) | 2016-12-09 | 2018-06-14 | The Uab Research Foundation | Chimeric chlorotoxin receptors |
| AU2018234827B2 (en) * | 2017-03-15 | 2024-04-04 | Orca Biosystems Inc. | Compositions and methods for hematopoietic stem cell transplants |
| WO2018229218A1 (en) * | 2017-06-14 | 2018-12-20 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-cd25 adc |
| EP3749334B1 (en) | 2018-02-08 | 2024-12-11 | The Board of Trustees of the Leland Stanford Junior University | Allogenic hematopoietic stem cell transplantation |
| EP3856206A1 (en) * | 2018-09-27 | 2021-08-04 | Phosphogam, Inc. | Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells |
| KR20200145328A (ko) | 2019-06-21 | 2020-12-30 | 안혜빈 | 자동 물분사 칠판지우개 |
| CN115175688A (zh) * | 2019-11-05 | 2022-10-11 | 耶达研究及发展有限公司 | 在数个t细胞介导的自身免疫性疾病的治疗中的数个否决细胞的用途 |
| WO2025122271A1 (en) * | 2023-12-08 | 2025-06-12 | IN8bio, Inc. | Methods of allogeneic hematopoietic stem cell transplantation and cancer treatment |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE361975T1 (de) * | 1993-05-17 | 2007-06-15 | Yeda Res & Dev | Tiermodell für hepatitis-virus infektion |
| CA2360046A1 (en) * | 1999-01-28 | 2000-08-03 | Lawrence S. Lamb, Jr. | In vitro activated gamma delta lymphocytes |
| US7078034B2 (en) * | 1999-01-28 | 2006-07-18 | Palmetto Health Alliance | In vitro activated γ δ lymphocytes |
| WO2003012060A2 (en) * | 2001-08-01 | 2003-02-13 | Jewish Hospital Healthcare Services, Inc. | Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| US20120269774A1 (en) * | 2006-09-21 | 2012-10-25 | Medistem Laboratories, Inc | Allogeneic stem cell transplants in non-conditioned recipients |
| EP2268293A2 (en) * | 2008-07-17 | 2011-01-05 | Smt. G R Doshi And Smt. K M Mehta Institute Of Kidney Diseases And Research Centre | Stem cell composition for inducing transplant tolerance |
| JP2013531043A (ja) | 2010-07-16 | 2013-08-01 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 癌の免疫療法のための方法及び組成物 |
| EP2686417B1 (de) * | 2011-03-17 | 2016-06-08 | Miltenyi Biotec GmbH | Tcralpha/beta-depletierte zellpräparationen |
| WO2012156958A2 (en) * | 2011-05-19 | 2012-11-22 | Instituto De Medicina Molecular | Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof |
| EP2717887B1 (en) * | 2011-06-09 | 2017-12-27 | University of Florida Research Foundation, Inc. | Methods for treating or preventing graft versus host disease |
| EP2785743B1 (en) | 2011-12-01 | 2019-08-14 | The Brigham and Women's Hospital, Inc. | Anti-ceacam1 recombinant antibodies for cancer therapy |
| US10434121B2 (en) * | 2011-12-22 | 2019-10-08 | Yeda Research And Development Co. Ltd. | Combination therapy for a stable and long term engraftment using specific protocols for T/B cell depletion |
| CA2926859A1 (en) * | 2013-10-25 | 2015-04-30 | Board Of Regents, The University Of Texas System | Polyclonal gamma delta t cells for immunotherapy |
| CN103834615A (zh) * | 2014-03-27 | 2014-06-04 | 叶永清 | 一种适用于培养γδT细胞的无血清培养基 |
| KR20180041229A (ko) * | 2015-08-25 | 2018-04-23 | 유에이비 리서치 파운데이션 | 줄기 세포 이식을 위한 방법 |
| CA3033876A1 (en) * | 2016-08-18 | 2018-02-22 | The Uab Research Foundation | Compositions and methods for cancer immunotherapy |
-
2016
- 2016-08-25 KR KR1020187008284A patent/KR20180041229A/ko not_active Ceased
- 2016-08-25 AU AU2016312610A patent/AU2016312610B2/en active Active
- 2016-08-25 ES ES16840139T patent/ES2984387T3/es active Active
- 2016-08-25 CA CA2996522A patent/CA2996522A1/en active Pending
- 2016-08-25 IL IL257678A patent/IL257678B2/en unknown
- 2016-08-25 EP EP24156525.8A patent/EP4458953A3/en active Pending
- 2016-08-25 CN CN201680053465.0A patent/CN108025023A/zh active Pending
- 2016-08-25 KR KR1020257010284A patent/KR20250048489A/ko active Pending
- 2016-08-25 JP JP2018510483A patent/JP7105188B2/ja active Active
- 2016-08-25 WO PCT/US2016/048738 patent/WO2017035375A1/en not_active Ceased
- 2016-08-25 CN CN202210691597.3A patent/CN115137752A/zh active Pending
- 2016-08-25 EP EP16840139.6A patent/EP3340997B1/en active Active
- 2016-08-25 US US15/754,973 patent/US20190183930A1/en not_active Abandoned
-
2022
- 2022-03-10 US US17/691,477 patent/US20220265720A1/en active Pending
- 2022-07-08 JP JP2022110221A patent/JP2022133453A/ja active Pending
-
2023
- 2023-05-11 AU AU2023202946A patent/AU2023202946A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525417A5 (enExample) | ||
| JP2018193377A5 (enExample) | ||
| JP2017533925A5 (enExample) | ||
| WO2015181641A3 (en) | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof | |
| JP2014114295A5 (enExample) | ||
| RU2014142267A (ru) | Лекарственное средство для лечения острого миелоидного лейкоза (омл) | |
| JP2016510326A5 (enExample) | ||
| EP4606430A3 (en) | Use of il-22 dimer in manufacture of a medicament for intravenous administration | |
| FI3383385T4 (fi) | Melflufeeniannoskuureja syöpään | |
| AU2018326364A1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease | |
| RU2018125622A (ru) | Способ применения карримицина против резистетности инфекции, спровоцированной микобактерией туберкулеза | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| HK1255481A1 (zh) | 用於治疗hcv的方法 | |
| MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
| RU2012136775A (ru) | Способ и средство для повышения адаптивных возможностей организма спортсменов в период тренировочного процесса | |
| RU2018102351A (ru) | Производные пиридин-3-ил уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека | |
| RU2014144404A (ru) | Железо (iii)-пиразин-комплексные соединения для лечения и профилактики явлений дефицита железа в организме и железодефицитной анемии | |
| CN202027889U (zh) | 一种注氢理疗帽 | |
| RU2013148539A (ru) | Алиспоривир для лечения инфекции вируса гепатита с | |
| RU2012114097A (ru) | Терапевтический агент против хронической боли | |
| RU2015133365A (ru) | Альфа-2 адренергический агонист для лечения внутриглазного давления и заболеваний глаз путем введения в стекловидное тело и внутрикамерно | |
| WO2006089120A3 (en) | Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury | |
| Cummins et al. | Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia | |
| Koop | Intramuscular calcifications: case report | |
| CN204766453U (zh) | 一种防摔的眼睛按摩仪 |